listed. Question 6. N N Incl : Incl: Incl: Provide warning if The Disclosure Permission W NIH, V 1.1 R41, R42, UT1, Disclosure Disclosure Permission Statement answer provided CDC, UT2, R43, R44, (NIH) Permission Statement answer is on the PHS398 Cover Page FDA, U43, U44 Statement (Y/N) different on Supplement form does not AHRQ, SBIR/STTR form and match the answer provided VA the Cover Page on the SBIR/STTR Supplement form Information form. Please verify and correct as needed. N N Incl : Incl: Incl: Cannot be submitted A Commercialization Plan E NIH, V 1.1 Plan R41, UT1, R43, for SBIR or STTR should not be submitted for CDC, (NIH) Attachment U43 Phase I. Phase I applications. FDA, AHRQ, VA N N Incl : Incl: Incl: Required for Phase II, The Commercialization Plan E NIH, V 1.1 Plan R42, UT2, R44, Direct Phase II and is required for Phase II and CDC, (NIH) Attachment U44 Fast Track Fast Track submissions. FDA, submissions AHRQ, VA N N Incl : Incl: Incl: Limited to 12 pages The Commercialization Plan E NIH, V 1.1 Plan R42, UT2, R44, is limited to twelve (12) CDC, (NIH) Attachment U44 pages. FDA, AHRQ, VA Question 8. 023.14 Receipt of (NIH) Phase II SBIR
listed. (NIH) Question 6. Disclosure Permission Statement (Y/N) N N Incl : NIH, CDC, FDA, AHRQ, VA Incl: V 1.1 Incl: R41, R42, UT1, UT2, R43, R44, U43, U44 Provide warning if Disclosure Permission Statement answer is different on SBIR/STTR form and the Cover Page Supplement form The Disclosure Permission Statement answer provided on the PHS398 Cover Page Supplement form does not match the answer provided on the SBIR/STTR Information form. Please verify and correct as needed. W (NIH) Plan Attachment N N Incl : NIH, CDC, FDA, AHRQ, VA Incl: V 1.1 Incl: R41, UT1, R43, U43 Cannot be submitted for SBIR or STTR Phase I. A Commercialization Plan should not be submitted for Phase I applications. E (NIH) Plan Attachment N N Incl : NIH, CDC, FDA, AHRQ, VA Incl: V 1.1 Incl: R42, UT2, R44, U44 Required for Phase II, Direct Phase II and Fast Track submissions The Commercialization Plan is required for Phase II and Fast Track submissions. E (NIH) Plan Attachment N N Incl : NIH, CDC, FDA, AHRQ, VA Incl: V 1.1 Incl: R42, UT2, R44, U44 Limited to 12 pages The Commercialization Plan is limited to twelve (12) pages. E (NIH) Question 8. Receipt of Phase II SBIR 023.14
eSub-validations-Oct2015%20.docx